^
Association details:
| Biomarker: | PAI1 elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib
Published date:
10/15/2020
Excerpt:
...serum samples were collected from 44 patients with mRCC before treatment and 4 weeks after axitinib initiation. Increased serum PAI-1 level from pre-treatment to 4 weeks after axitinib initiation was an independent prognostic marker for shorter PFS and OS in multivariate analyses (P = .015 and P = .032, respectively).
DOI:
10.1002/hsr2.197
